Blood Disorder News and Research

RSS

TGen, Virginia G. Piper Cancer Center and Side-Out Foundation team up for breast cancer study

Many women live with breast cancer that does not respond to standard medical treatment, a condition that researchers at the Virginia G. Piper Cancer Center at Scottsdale Healthcare want to change by aggressively targeting specific genes.

12 Mar 2010

Side-Out Foundation sponsors new advanced breast cancer clinical trial

The Side-Out Foundation, which pairs volleyball enthusiasts with breast cancer researchers, is sponsoring a new clinical trial for up to 25 patients with advanced breast cancer.

10 Mar 2010

Rare Disease Day 2010: Alexion Pharmaceuticals joins NORD and EURORDIS to raise awareness

Alexion Pharmaceuticals, Inc., has joined the National Organization for Rare Disorders (NORD) and the European Organization for Rare Diseases (EURORDIS) in supporting the goals of the third annual Rare Disease Day, February 28, 2010.

26 Feb 2010

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

The new decade may herald an era of cell therapy -- treating human diseases by delivering highly specific beneficial cells. In the wake of an NIH decision late last year permitting federally funded researchers to use new lines of human embryonic stem cells, the door has opened more widely to stem cell research.

16 Feb 2010

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.

11 Feb 2010

Statins may protect SCD children from pneumococcal infection

New research suggests a family of widely used cholesterol-lowering drugs might help protect individuals from serious illness following bacterial infection, including the pneumococcal infections that pose a deadly threat to those with sickle cell disease.

20 Jan 2010

New research may yield more effective treatment for childhood leukemia

A team of Israeli scientists at the Sheba Medical Center's Research Center for Leukemia and Childhood Malignancies has discovered a method for developing a more effective and less perilous treatment for those suffering from childhood leukemia, the most common cancer in children.

6 Jan 2010

GSK receives European CHMP positive opinion for Revolade

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

18 Dec 2009

Retrospective study demonstrates new survival data for patients with myelofibrosis

A recent study, published in the December issue of Mayo Clinic Proceedings, demonstrates new survival data for the blood disorder myelofibrosis. This retrospective study is the largest ever conducted in young patients with primary myelofibrosis.

15 Dec 2009

Statewide blood screening program identifies infants with T-cell lymphopenia

The testing of DNA from a statewide blood screening program for newborns in Wisconsin was able to identify infants with T-cell lymphopenia, a blood disorder that affects the child's immune system, a disease in which early identification is important, according to a study in the December 9 issue of JAMA.

9 Dec 2009

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Sickle cell disease, a condition characterized by deformed and dysfunctional red blood cells, is one of the most common genetic blood disorders affecting millions of people around the world, including more than 70,000 Americans (National Heart, Lung, and Blood Institute.

8 Dec 2009

New genetic approach may hold promise for sickle cell disease

A new genetic approach to treating sickle cell disease is showing promising results in mice, report researchers from Children's Hospital Boston. By inactivating a gene they previously discovered to be important in the laboratory, they were able to boost production of a healthy fetal form of hemoglobin in the mice, potentially compensating for the defective adult hemoglobin that causes red blood cells to "sickle" and obstruct blood flow.

8 Dec 2009

Alexion Pharmaceuticals announces positive data from AEGIS study of Soliris

Alexion Pharmaceuticals, Inc. today announced positive data from the 26-week extension of the AEGIS study, an open-label registration study examining Soliris® (eculizumab) for the treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH).

7 Dec 2009

New data shows patients with Type II PNH cells experience platelet consumption and increased thrombosis risk

Alexion Pharmaceuticals, Inc. today announced presentation of data showing that the presence of Type II paroxysmal nocturnal hemoglobinuria (PNH) cells is correlated with thrombocytopenia, potentially indicating that patients with Type II cells experience ongoing platelet consumption and increased thrombosis risk.

7 Dec 2009

Study finds substantial variation in hydroxyurea utilization for sickle cell disease

A new study by researchers from the Medical College of Wisconsin, in Milwaukee, found a substantial variation in hydroxyurea utilization for pain and other sickle cell disease complications in children.

7 Dec 2009

New discoveries to treat life-threatening blood disorder presented at ASH annual meeting

A genetic variation that may indicate a patient's risk of developing a potentially life-threatening blood disorder if exposed to certain pharmaceutical therapies or chemicals is one of several medical discoveries scientists at cancer diagnostics leader Quest Diagnostics will present during the 51st American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2009, in New Orleans, LA.

4 Dec 2009

ASH to host annual High School Student Symposium at New Orleans Marriott

The American Society of Hematology (ASH) will host its annual High School Student Symposium at the New Orleans Marriott on Thursday, December 3, at 8:00 a.m. CST.

1 Dec 2009

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Alexion Pharmaceuticals, Inc. today announced that researchers are scheduled to present data relating to Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 51st Annual Meeting of the American Society of Hematology (ASH), to be held December 5 – 8, 2009 at the Ernst N. Morial Convention Center in New Orleans.

11 Nov 2009

National study to prevent strokes in children and adolescents with sickle cell anemia

St. Jude Children's Research Hospital investigators were recently awarded a $23 million federal grant to launch a national study of the drug hydroxyurea to prevent first strokes in children and adolescents with sickle cell anemia (SCA).

29 Oct 2009

Dig Pink Volleyball Breast Cancer Awareness campaign to raise $1 million in support of breast cancer research

The Side-Out Foundation and its Dig Pink- Volleyball Breast Cancer Awareness campaign will launch a first of its kind clinical trial this month to examine the effects of individualized treatment on patients with metastatic breast cancer.

23 Oct 2009

Blood Disorder News and Research

TGen, Virginia G. Piper Cancer Center and Side-Out Foundation team up for breast cancer study

Side-Out Foundation sponsors new advanced breast cancer clinical trial

Rare Disease Day 2010: Alexion Pharmaceuticals joins NORD and EURORDIS to raise awareness

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Statins may protect SCD children from pneumococcal infection

New research may yield more effective treatment for childhood leukemia

GSK receives European CHMP positive opinion for Revolade

Retrospective study demonstrates new survival data for patients with myelofibrosis

Statewide blood screening program identifies infants with T-cell lymphopenia

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

New genetic approach may hold promise for sickle cell disease

Alexion Pharmaceuticals announces positive data from AEGIS study of Soliris

New data shows patients with Type II PNH cells experience platelet consumption and increased thrombosis risk

Study finds substantial variation in hydroxyurea utilization for sickle cell disease

New discoveries to treat life-threatening blood disorder presented at ASH annual meeting

ASH to host annual High School Student Symposium at New Orleans Marriott

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

National study to prevent strokes in children and adolescents with sickle cell anemia

Dig Pink Volleyball Breast Cancer Awareness campaign to raise $1 million in support of breast cancer research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News